This bill aims to eliminate the termination date for the prohibition against pharmacy benefit managers or health carriers requiring federally certified health entities to identify 340B drugs. To achieve this, the bill repeals specific sections from previous laws, namely Section 26 of Chapter 501 from 2021 and Section 1 of Chapter 259 from 2023.

Additionally, the bill includes a provision for an immediate effective date upon passage and approval, ensuring that the changes take effect without delay. This legislative action seeks to maintain the current protections for health entities regarding the identification of 340B drugs, thereby supporting their operational integrity.